Aster DM Healthcare Limited's Board of Directors has approved a significant leadership appointment during their meeting held on March 10, 2026. The board unanimously decided to appoint company founder Dr. Azad Moopen as Executive Director, marking a strategic leadership transition for the healthcare organization.

Board Meeting Details and Approval Process

The board meeting, which commenced at 03:30 P.M. (IST) and concluded at 04:15 P.M. (IST), saw directors deliberate on the appointment based on recommendations from the Nomination and Remuneration Committee and approval from the Audit Committee. The decision represents a redesignation of Dr. Moopen from his previous role as Managing Director, while he continues to serve as Chairman of the company.

Leadership Profile and Experience

Dr. Azad Moopen brings extensive healthcare industry experience and institutional knowledge to his new role. As the company's founder, he has been associated as a director since the organization's establishment, playing a pivotal role in transforming a single-doctor clinic established in Dubai in 1987 into a leading global healthcare organization.

His academic credentials include:

• Gold Medalist in MBBS from Calicut Government Medical College, Kerala
• Post-Graduate in General Medicine from Calicut Government Medical College, Kerala
• Diploma in Chest Diseases from Delhi University, India

Family Connections and Governance

The appointment disclosure reveals family relationships within the company's leadership structure. Dr. Azad Moopen's daughters, Ms. Alisha Moopen and Dr. Zeba Azad Moopen, currently serve as Deputy Managing Director and Non-Executive Director respectively, highlighting the family's continued involvement in the organization's governance.

Regulatory Compliance and Next Steps

The appointment has been structured in full compliance with SEBI regulations, specifically Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has confirmed that Dr. Azad Moopen is not debarred from holding the office of Director by virtue of any SEBI Order or any other authority.

The appointment remains subject to shareholder approval through postal ballot, representing the final step in the approval process. This appointment reflects the board's confidence in Dr. Moopen's leadership capabilities and his integral role in maintaining stakeholder trust and organizational stability.

Aster DM Healthcare Limited conducted a meeting of unsecured trade creditors on March 10, 2026, as part of the regulatory process for its proposed scheme of amalgamation with Quality Care India Limited. The meeting was held pursuant to directions from the Hon'ble National Company Law Tribunal (NCLT), Hyderabad bench, and marks a significant step in the corporate restructuring process.

Meeting Details and Participation

The creditors meeting was conducted through Video Conferencing (VC) and Other Audio Visual Means (OAVM) at 02:00 P.M. IST on Tuesday, March 10, 2026. The virtual format ensured compliance with applicable provisions while maintaining accessibility for stakeholders.

Scheme of Amalgamation Framework

The meeting focused on the proposed scheme of amalgamation between Quality Care India Limited (Transferor Company) and Aster DM Healthcare Limited (Transferee Company), along with their respective shareholders and creditors. The scheme was presented for consideration and approval by the unsecured trade creditors as mandated by the NCLT order dated January 21, 2026.

Mr. Sunil Kumar M R, Chief Financial Officer, addressed the creditors on the salient features of the proposed scheme. The presentation was followed by an interactive session where registered speakers among the unsecured trade creditors sought clarifications through VC/OAVM. The company's management team provided comprehensive responses to all queries raised during the session.

Voting Process and Procedures

The company implemented a comprehensive electronic voting system to ensure transparent and efficient decision-making. The voting process included two components designed to maximize participation among stakeholders.

Mr. Hemish Purushottam, Company Secretary and Compliance Officer, provided detailed instructions on the voting procedure and other meeting-related guidelines. The electronic voting was conducted under the supervision of the NCLT-appointed scrutinizer to ensure compliance with the Companies Act, 2013 and SEBI Listing Regulations.

Regulatory Compliance and Documentation

The meeting proceedings were conducted in strict compliance with applicable provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. All requisite documentation, including the Notice of Meeting, Explanatory Statement, and the proposed scheme, had been circulated to creditors prior to the meeting.

The company confirmed that voting results, along with the consolidated report from the scrutinizer, would be disseminated to stock exchanges where the company's equity shares are listed. Additionally, the results will be made available on the company's website and National Securities Depository Limited (NSDL) website within prescribed timelines, ensuring transparency and regulatory compliance throughout the process.